pegozafermin
AssetAlso BIO89-100, TEV-47948
Long-acting glycopegylated FGF21 analog that regulates lipid and glucose metabolism.
- Stage
- Phase 3
- Modality
- Protein or enzyme
- Target
- Insulin/IGF-1 signalling
- 2
- Indications
- 2
- Trials
- 1
- Developer
Indications
2Metabolic dysfunction-associated steatohepatitis (mash) / nonalcoholic steatohepatitis (nash) with compensated cirrhosis
Phase 3, Recruiting, NCT06419374, clinicaltrials.gov, 7 Oct 2026
Metabolic dysfunction-associated steatotic liver disease (mash) / nonalcoholic steatohepatitis (nash) with fibrosis
Phase 3, Recruiting, NCT06318169, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains7
- Owner and partners1
- Trials2
- Evidence for its targets7
- Competitors6
- Aging relevance2
- Signals3
Every asset’s record: target, stage, trials and the evidence behind it.